HY-125033 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    MedChemExpress eidd 1931
    Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining <t>molnupiravir</t> (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).
    Eidd 1931, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eidd 1931/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    eidd 1931 - by Bioz Stars, 2022-07
    94/100 stars
      Buy from Supplier

    86
    Pfizer Inc eidd 1931
    Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining <t>molnupiravir</t> (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).
    Eidd 1931, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eidd 1931/product/Pfizer Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    eidd 1931 - by Bioz Stars, 2022-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining molnupiravir (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).

    Journal: bioRxiv

    Article Title: Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2-host protein-protein interaction network

    doi: 10.1101/2022.06.03.494640

    Figure Lengend Snippet: Dose-response matrix of SARS-CoV-2-infected 293TAT cells when combining molnupiravir (MPV, EIDD-1931) with either (A) MPA or (B) merimepodib. The maximum synergistic area (MSA, dotted-line square) and the Bliss synergy score were calculated with SynergyFinder v2.0, both for efficacy (virus infection) and viability (toxic effect on non-infected cells). Selective efficacy quantifies the difference in inhibition of virus-infected and mock-infected cells. A selective efficacy of 100 means that the drug combination inhibits 100% of the virus-infected cells and does not affect the mock-infected, drug-treated cells, while a selective efficacy of 0 means the drug kills both the virus and mock-infected cells. The selective efficacies of 46% and 35% for combinations of molnupiravir with MPA and merimepodib, respectively, indicate relatively high selective suppression of virus infection only. This is also seen in minimal co-inhibition of the viability of non-infected cells (right).

    Article Snippet: Compounds vorinostat (catalogue number S1047; Sellckchem), romidespin (catalogue number S3020; Sellckchem), spautin-1 (catalogue number S7888; Sellckchem), fedratinib (catalogue number S2736; Sellckchem), merimepodib (catalogue number S6689; Sellckchem), mycophenolic acid (catalogue number HYB0421; MedChem Express), (+)-JQ-1 (catalogue number HY13030; MedChem Express) and Molnupiravir (catalogue number HY125033 MedChem Express) were tested.

    Techniques: Infection, Inhibition